U.S. Pharma is largely immune from 'MAHA' impact: Wolfe
Wolfe projects a positive outlook for Pharma & Large-Cap Biotech stocks despite potential policy changes as part of Make America Healthy Again movement. Read more here.
bovnews13h
What’s Driving Biogen Inc (BIIB) Stock’s -12.76% Plunge Over the Past Month?
On Thursday, Biogen Inc (BIIB) stock saw a decline, ending the day at $164.89 which represents a decrease of $-0.90 or -0.54% from the prior close of $165.79. The stock opened at $165 and touched a ...
Cautious Optimism for Biogen: Hold Rating Amidst European Approval Developments
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...
Fintel on MSN19h
Citigroup Initiates Coverage of Biogen (BIIB) with Neutral Recommendation
Fintel reports that on November 14, 2024, Citigroup initiated coverage of Biogen (NasdaqGS:BIIB) with a Neutral ...
Fintel on MSN19h
Wolfe Research Initiates Coverage of Biogen (BIIB) with Peer Perform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Biogen (NasdaqGS:BIIB) with a Peer Perform ...